Sailesh T Desai retires from Sun Pharma Board of Directors

Published On 2024-03-30 06:22 GMT   |   Update On 2024-03-30 06:23 GMT

Maharashtra: Through a recent BSE filing, Sun Pharma has informed that Sailesh Trambaklal Desai will retire from the Company's Board of Directors, as he is completing his term as a Director on March 31, 2024."This is to inform that Mr. Sailesh Trambaklal Desai (DIN: 00005443) retires from the Board of Directors of the Company upon completion of his term as a Director on March 31, 2024,"...

Login or Register to read the full article

Maharashtra: Through a recent BSE filing, Sun Pharma has informed that Sailesh Trambaklal Desai will retire from the Company's Board of Directors, as he is completing his term as a Director on March 31, 2024.

"This is to inform that Mr. Sailesh Trambaklal Desai (DIN: 00005443) retires from the Board of Directors of the Company upon completion of his term as a Director on March 31, 2024," the Company stated.

Sailesh T. Desai has more than 28 years of industrial experience, 18 of which have been in the pharmaceutical industry. Desai has extensive and comprehensive corporate affairs experience, being involved in the turnaround at Milmet prior to Sun Pharma’s acquisition, as well as in the early stages of the company’s growth. He holds a BSc degree from the University of Calcutta.

Read also: Sun Pharma to buy 16.33 percent stake in Surgimatix for over Rs 25 crore

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

Read also: Sun Pharma gets Australian regulatory nod for acne vulgaris treatment Winlevi



Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News